Pelage Pharmaceuticals is a technology company.
Pelage Pharmaceuticals has raised $120.0M across 1 funding round.
Pelage Pharmaceuticals has raised $120.0M in total across 1 funding round.
Pelage Pharmaceuticals has raised $120.0M in total across 1 funding round.
Pelage Pharmaceuticals's investors include ARCH Venture Partners.
Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotech company developing PP405, a novel topical small-molecule gel that activates dormant hair follicle stem cells to treat androgenetic alopecia, the most common form of hair loss affecting over 80% of men and 40% of women lifetime.[1][2][5] It serves men and women of all skin and hair types underserved by existing FDA-approved treatments like minoxidil (Rogaine) and finasteride (Propecia), which have limited efficacy, side effects, and no regenerative mechanism.[3][5] PP405 targets mitochondrial pyruvate carrier (MPC1/MPC2) proteins to build up pyruvate, stimulating lactate dehydrogenase and stem cell activity for new hair growth, even from previously bald follicles; it's non-invasive with no systemic exposure and is in Phase 2 trials started mid-2024.[2][5][6] The company shows strong growth momentum with $14M Series A/A-1 led by GV (Google Ventures), a nine-figure Series B co-led by Arch Venture Partners and GV in 2025, Phase 1 safety success, and plans for late-stage trials.[1][2][5]
Pelage emerged from UCLA's Magnify Incubator at the California NanoSystems Institute, licensing proprietary patents from the University of California for small molecules targeting hair follicle stem cell metabolism.[3] The idea stemmed from stem cell biology research revealing how dormant follicles can be reactivated via metabolic pathways, addressing gaps in current therapies amid a $7B+ annual hair loss market serving 400M people worldwide.[2][3] Key early milestones include Phase 1 data in 2024 showing safety and statistically significant stem cell activation after one week, recruitment for inclusive Phase 2 trials in 2025, appointing dermatology leaders to its Clinical Advisory Board, and naming Qing Yu Christina Weng, M.D., as Chief Medical Officer.[1][2] Led by CEO Daniel Gil, the Los Angeles-based firm has rapidly advanced to clinical validation, fueled by top-tier VC backing.[5]
Pelage rides the regenerative medicine wave in biotech, leveraging stem cell biology and metabolic targeting amid aging population demands and a $7B+ underserved hair loss market dominated by ineffective legacy drugs.[2][3][5] Timing aligns with advances in topical delivery and mitochondrial research, positioning it ahead of injectables or gene therapies while broader forces like inclusive clinical trials and VC interest in "aging gracefully" therapeutics favor scalable solutions.[1][5] It influences the ecosystem by validating non-invasive regeneration for dermatology, potentially expanding to other fibrosis-related conditions, and drawing talent/investment to LA's biotech hub via UCLA ties.[3][5]
Pelage is primed for a 2026 Phase 2 readout and Phase 3 launch, potentially yielding the first truly regenerative, accessible hair loss therapy and FDA approval by late decade, backed by its nine-figure war chest.[5] Trends like personalized regen-med, AI-accelerated trials, and demand for side-effect-free cosmetics will propel it, evolving its influence from niche alopecia leader to broader stem cell platform player. This positions Pelage to transform a stagnant market, reigniting natural hair growth for millions as promised in its stem cell-rooted mission.[2]
Pelage Pharmaceuticals has raised $120.0M across 1 funding round. Most recently, it raised $120.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $120.0M Series B | ARCH Venture Partners |